DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Naproxenis the generic ingredient in twelve branded drugs marketed by Atnahs Pharma Us, Amneal, Hikma, Novitium Pharma, Actavis Elizabeth, Fosun Pharma, Mylan Pharms Inc, Nuvo Pharms Inc, Pliva, Teva, Amneal Pharms Ny, Aurobindo Pharma Ltd, Chartwell Molecules, Dava Pharms Inc, Glenmark Generics, Granules, Hamilton Pharms, Hikma Intl Pharms, Invagen Pharms, Ivax Sub Teva Pharms, Marksans Pharma, Mylan, Perrigo Pharms Co, Purepac Pharm, Roxane, Sciegen Pharms Inc, Teva Pharms, Watson Labs, Watson Labs Teva, Zydus Pharms Usa, Bionpharma Inc, Catalent, Puracap Pharm Llc, Almatica, Actavis Labs Fl Inc, Bayer, Able, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Lnk Intl Inc, Novelgenix Theraps, Perrigo, Pld Acquisitions Llc, Sandoz, Sun Pharm Inds Ltd, Yichang Humanwell, Sun Pharm, and Currax, and is included in eighty-three NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.
There are forty-two drug master file entries for naproxen. Fifty-one suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for NAPROXEN
|Drug Master File Entries:||42|
|Finished Product Suppliers / Packagers:||51|
|Raw Ingredient (Bulk) Api Vendors:||116|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price trends for NAPROXEN|
|Drug Sales Revenues:||Drug sales revenues for NAPROXEN|
|What excipients (inactive ingredients) are in NAPROXEN?||NAPROXEN excipients list|
|DailyMed Link:||NAPROXEN at DailyMed|
Recent Clinical Trials for NAPROXEN
Identify potential brand extensions & 505(b)(2) entrants
|Turku University Hospital||Phase 4|
|Eurofarma Laboratorios S.A.||Phase 3|
|University of Pennsylvania||Phase 4|
Generic filers with tentative approvals for NAPROXEN
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for NAPROXEN
|Drug Class||Nonsteroidal Anti-inflammatory Drug |
|Mechanism of Action||Cyclooxygenase Inhibitors |
Medical Subject Heading (MeSH) Categories for NAPROXEN
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.